Dose‐dependent glucosuria of DWP16001, a novel selective sodium–glucose cotransporter‐2 inhibitor, in healthy subjects-Reference-Cited by-同舟云学术

Dose‐dependent glucosuria of DWP16001, a novel selective sodium–glucose cotransporter‐2 inhibitor, in healthy subjects

Published:2022-04-22 Issue:9 Volume:88 Page:4100-4110
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Hwang Jun Gi¹²^ORCID,Lee SeungHwan¹^ORCID,Huh Wan³,Han Jumi³,Oh Jaeseong¹^ORCID,Jang In‐Jin¹^ORCID,Yu Kyung‐Sang¹^ORCID

Affiliation:

1. Department of Clinical Pharmacology and Therapeutics Seoul National University College of Medicine and Hospital Seoul Republic of Korea

2. Department of Clinical Pharmacology and Therapeutics Chungbuk National University College of Medicine and Hospital Chungcheongbuk‐do Republic of Korea

3. Daewoong Pharmaceutical Co., Ltd. Seoul Republic of Korea

Funder

Daewoong Pharmaceutical Company

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15348

Reference39 articles.

1. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition

2. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020

3. Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long‐term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: A 52‐week extension of a Phase 3 randomized controlled trial;Diabetes, Obesity and Metabolism;2024-07-26

2. The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium‐glucose cotransporter‐2 inhibitor, in type 2 diabetes;Diabetes, Obesity and Metabolism;2024-04-15

3. A 52‐week efficacy and safety study of enavogliflozin versus dapagliflozin as an add‐on to metformin in patients with type 2 diabetes mellitus: ENHANCE‐M extension study;Diabetes, Obesity and Metabolism;2024-03-08

4. Efficacy and safety of enavogliflozin vs. dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus based on renal function: a pooled analysis of two randomized controlled trials;Cardiovascular Diabetology;2024-02-15

5. Efficacy and safety of enavogliflozin vs. dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus based on renal function: A pooled analysis of two randomized controlled trials;2024-01-10